Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 9:2020:2042636.
doi: 10.1155/2020/2042636. eCollection 2020.

Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study

Clémentine Carlet  1 , Damien Bichard  2 , Marie Aleth Richard  3 , Emmanuel Mahé  4 , Clémence Saillard  5 , Emilie Brenaut  6 , Alain Dupuy  5 , Laurent Misery  6 , Axel Villani  7 , Denis Jullien  7 , Eve Puzenat  1 , Charlée Nardin  1 , François Aubin  1 , Groupe de Recherche Sur le Psoriasis de la Société Française de Dermatologie  8
Affiliations

Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study

Clémentine Carlet et al. Dermatol Res Pract. .

Abstract

Background: Although infliximab (IFX) has been available since 2005, there are very little data on the long-term drug survival of infliximab in real-life.

Objective: Our aim was to identify and describe psoriasis patients treated with IFX for longer than 6 years.

Methods: Psoriasis patients treated with IFX for longer than 6 years were retrospectively included. Demographic and clinical data were collected in May 2018.

Results: Between January 2005 and December 2012, 43 patients were maintained on IFX for 6 years or longer. IFX was introduced as a 4.5 line of systemic therapy. The mean duration of IFX treatment was 8.5 years (6-12). In May 2018, 30 patients (70%) were still maintained on IFX at 4-6 mg/kg every 8-10 weeks with an efficiency of about 100%. IFX was stopped in 13 patients (30%) mainly for loss of efficacy in 6 patients (46%). Three patients developed solid cancer including bladder cancer, lung cancer, and prostate cancer. Limitation. Retrospective study.

Conclusion: We report the efficacy and safety of IFX maintained for up to 12 years in psoriasis patients. The long-term use of IFX was associated with a high BMI confirming the critical role of weight-based dosing for this drug.

PubMed Disclaimer

Conflict of interest statement

François Aubin, Emmanuel Mahé, Denis Jullien, and Marie Aleth Richard received honoraria as a consultant and/or investigator and/or speaker for and/or have been reimbursed for conference attendance by Abbvie, Amgen, Boehringer, Celgene, GSK, Janssen-Cilag, Leo Pharma, Lilly, MSD, Nordic, Novartis, Pfizer, MSD, Sanofi, and Sandoz. Axel Villani received honoraria as a consultant for Novartis and Janssen-Cilag.

References

    1. Sbidian E., Chaimani A., Garcia-Doval I., et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews. 2017;12 - PMC - PubMed
    1. Shear N. H., Hartmann M., Toledo-Bahena M., et al. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. British Journal of Dermatology. 2014;171(3):631–641. doi: 10.1111/bjd.13004. - DOI - PubMed
    1. Nast A., Jacobs A., Rosumeck S., Werner R. N. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. Journal of Investigative Dermatology. 2015;135(11):2641–2648. doi: 10.1038/jid.2015.206. - DOI - PubMed
    1. Sbidian E., Mezzarobba M., Weill A., Coste J., Rudant J. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM) British Journal of Dermatology. 2019;180(1):86–93. doi: 10.1111/bjd.16809. - DOI - PubMed
    1. Lin P. T., Wang S. H., Chi C. C. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Scientific Reports. 2018;8(1):p. 16068. doi: 10.1038/s41598-018-34293-y. - DOI - PMC - PubMed

LinkOut - more resources